Lipid-independent effects of an estrogen–statin combination: inhibition of expression of adhesion molecules and plasminogen activator inhibitor-1 in human endothelial cell cultures

References

• Petersen LR. Estrogen replacement therapy and coronary artery disease. Curr Opin Cardiol 1998;13:223–31
   PubMed Web of Science ®Google Scholar
• Hulley ST, Grady D, Bush T, et al., for the Heart and Estrogen/progestin Replacement Study (HERS) research group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. J Am Med Assoc 1998;280:605–13
   Google Scholar
• Gaw A, Packard CJ, Shepherd J, eds. Statins: The HMG CoA Reductase Inhibitors in Perspective. London: Martin Dunitz, 2000
   Google Scholar
• Darling GM, Johns JA, McCloud PI, Davis SR. Estrogen and progestin compared with simva-statin for hypercholesterolemia in postmeno-pausal women. N Engl J Med 1997;337:595–601
   PubMed Web of Science ®Google Scholar
• Darling GM, Johns JA, McCloud PI, Davis SR. Concurrent use of simvastatin and estrogen—progestin therapy compared with each therapy alone for hypercholesterolemia in postmeno-pausal women. Climacteric 1999;2:181–8
   PubMedGoogle Scholar
• Averbuch M, Ayalon D, Eckstein N, et al. Hormone replacement therapy and simvastatin in the therapy of hypercholesterolemic post-menopausal women. J Med 1998;29:343–50
   PubMedGoogle Scholar
• Sbarouni E, Kyriakides ZS, Kremastinos DTh. The effect of hormone replacement therapy alone and in combination with simvastatin on plasma lipids of hypercholesterolemic postmenopausal women with coronary heart diesease. J Am Coll Cardiol 1998;32:1244–50
   Google Scholar
• Koh KK, Cardillo C, Bui MN, et al. Vascular effects of estrogen and cholesterol-loweringtherapies in hypercholesterolemic postmeno-pausal women. Circulation 1999;99:354–60
   PubMed Web of Science ®Google Scholar
• Vane JR, Botting RM. Regulatory mechanisms of the vascular endothelium: an update. Pol J Pharmacol 1994;46:499–521
   PubMedGoogle Scholar
• Abrams J. Role of endothelial dysfunction in coronary disease. Am J Cardiol 1997;79:2–9
   PubMedGoogle Scholar
• Mendelsson ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999;340:1801–11
   PubMed Web of Science ®Google Scholar
• Vaughan CJ, Murphy MB, Buckley BM. Statins do more than just lower cholesterol. Lancet 1996;348:1079–82
   Google Scholar
• Chia MC. The role of adhesion molecules in atherosclerosis. Crit Rev Clin Lab Sci 1998;35: 573–602
   PubMed Web of Science ®Google Scholar
• Ridker PM, Hennekens CH, Roitman-Johnson B, Stampfer MJ, Allen J. Plasma concentration of soluble intercellular adhesion molecule 1 and risk of future myocardial infarction in apparently healthy men. Lancet 1998;351: 88–92
   Google Scholar
• Lourdes-Ponce M, Cid MC, Kim-Schulze S, etal. Role of estrogen in endothelial cell behaviour. Rubanyi G, Kauffman R, eds. In Estrogen and the Vessel Wall. Amsterdam: Harwood Academic Publishers: 1998,63–72
   Google Scholar
• Caulin-Glaser T, Sessa WC, Bender JR. Modula-tion of cellular adhesion molecules and endo-thelial nitric oxide synthase by estrogen. Rubanyi G, Kauffman R, eds. In Estrogen and the Vessel Wall. Amsterdam: Harwood Academic Publishers, 1998: 73–90
   Google Scholar
• Koh KK, Bui MN, Mincemoyer R, Cannon RO III. Effects of hormone therapy on inflammatory cell adhesion molecules in postmenopausal women. Am J Cardiol 1997;80:1505–7
   Google Scholar
• Caulin-Glaser T, Farrell WJ, Pfau SE, et al. Modulation of circulating cellular adhesion molecules in postmenopausal women with coro-nary artery disease. J Am Coll Cardiol 1998;31: 1555–60
   Google Scholar
• Romano M, Mezzetti A, Marulli C, et al. Fluva-statin reduces soluble P-selectin and ICAM-1 levels in hypercholesterolemic patients: role of nitric oxide. J Invest Med 2000;48:183–9
   PubMed Web of Science ®Google Scholar
• Kohler HP, Grant PJ. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med 2000;342:1792–801
   PubMed Web of Science ®Google Scholar
• Koh KK, Mincemoyer R, Bui MN, etal. Effects of hormone replacement therapy on fibrinolysis in postmenopausal women. N Engl J Med 1997; 336:683–90
   PubMed Web of Science ®Google Scholar
• Mussoni L, Banfi C, Sironi L, Arpaia M, Tremoli E. Fluvastatin inhibits basal and stimulated plasminogen activator inhibitor 1, but increases tissue type plasminogen activator in cultured human endothelial cells. Tbromb Haemost 2000; 84:59–64
   Google Scholar
• Bourcier T, Libby P. HMG CoA reductase inhibi-tors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells. Arterioscler Tbromb Vasc Biol 2000;20:556–62
   PubMed Web of Science ®Google Scholar
• Vigna GB, Donega P, Passaro A, et al. Post-prandial effects of gemfibrozil vs. simvastatin in hypercholesteremic subjects with borderline hypertriglyceridemia. Nutr Me tab Cardiovasc Dis 1999;9:234–43
   PubMed Web of Science ®Google Scholar
• Plosker GL, Wagstaff AJ. Fluvastatin — a review of its pharmacology and use in management of hypercholesterolaemia. Drugs 1996;51:433–459
   PubMed Web of Science ®Google Scholar
• Seeger H, Lippert C, Wallwiener D, Mueck AO. Effect of fluvastatin and estradiol on the produc-tion of prostacyclin and endothelin in human umbilical vein endothelial cells. Pbarm Pbarma-col Lett 2000;1:16–18
   Google Scholar
• Cushman M, Legault C, Barrett-Connor E, et al. Effect of postmenopausal hormones on inflam-mation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEP!) study. Circulation 1999;100:717–22
   Google Scholar
• Ridker PM, Hennekens CH, Rifai N, Buring JE, Manson JE. Hormone replacement therapy and increased plasma concentrations of C-reactive protein. Circulation 1999;100:713–16
   Google Scholar